A Long-term Extension Study of PCI-32765 (Ibrutinib)

Clinical trial NCT01804686 · RECRUITING

Trial details

NCT number: NCT01804686
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Diffuse Large B-cell Lymphoma Waldenstrom Macroglobulinemia Chronic Graft Versus Host Disease

Start date: 2013-09-09
Primary completion: 2026-12-31
Enrollment: 700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.